Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors.

ABSTRACT:

Importance

Immune checkpoint inhibitors (CPIs) are now part of standard therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) because of improved outcomes compared with chemotherapy in clinical trials. However, data on outcomes in patients with HNSCC in the general population who are treated with CPIs remain limited.

Objective

To assess response rates, survival outcomes, and associations with key clinical covariates in a large, contemporary cohort of patients with recurrent or metastatic mucosal HNSCC who were treated with CPIs with or without chemotherapy.

Design, setting, and participants

This retrospective cohort study included patients older than 18 years who received CPI-based therapy for recurrent or metastatic HNSCC at

SUBMITTER: Hobday SB 

PROVIDER: S-EPMC9389441 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature